<DOC>
	<DOCNO>NCT01648153</DOCNO>
	<brief_summary>GSK1070806 humanise IgG1/kappa antibody direct soluble cytokine interleukin-18 ( IL-18 ) . The aim placebo control study evaluate efficacy , safety , tolerability , pharmacokinetics pharmacodynamics GSK1070806 obese subject Type 2 diabetes mellitus ( T2DM ) , gain good understand mechanism GSK1070806 exert therapeutic effect .</brief_summary>
	<brief_title>Investigate Efficacy Safety GSK1070806 Obese Subjects With T2DM</brief_title>
	<detailed_description>The study randomise , single-blind ( sponsor-unblinded ) , placebo-controlled , study investigate efficacy , safety , tolerability , pharmacokinetics pharmacodynamics repeat intravenous infusion ( 2 dose 4-weeks apart ) GSK1070806 obese patient T2DM . The primary objective study assess improvement fast postprandial glucose control . This parallel-group study 30 obese subject T2DM poorly control metformin monotherapy ( HbA1C &gt; 7 % &lt; 9.5 % ) , level microalbuminuria indicative progressive kidney disease i.e . 30-300mg/L albumin urine ACR ≥3.5 mg/mmol ( female ) ≥2.5 mg/mmol ( male ) ≤30mg/mmol . There three treatment group comprise two active one placebo arm 10 subject per dose group . The study contain broad range biomarker assessment , purpose evaluate mechanistic basis GSK1070806 exert therapeutic benefit subject T2DM . Subjects randomise one three treatment group receive two intravenous infusion GSK1070806 placebo twenty-eight day apart . A MMT challenge conduct Day 1 , Day 29 , Day 57 Day 85 evaluation primary endpoint .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>1 . A diagnosis T2DM determine responsible physician base medical evaluation include medical history , physical examination , laboratory test , onset least 6 month prior Screening . 2 . Male female 18 70 year age inclusive , time signing informed consent . 3 . HbA1c level ≥ 7.0 % ≤ 9.5 % ; Screening . 4 . On stable dose monotherapy metformin three month prior screen , total daily dose great equal 1000 mg least 2 month prior dose . 5 . Fasting plasma glucose level &lt; 13.3 mmol/L ( 240 mg/dL ) screening . 6 . Obese BMI ≥ 30 kg/m2 , &lt; 40 kg/m2 . 7 . Presence microalbuminuria : 30300mg/L albumin urine Albumin Creatinine Ratio ( ACR ) ≥ 3.5 mg/mmol ( female ) ≥2.5 mg/mmol ( male ) ≤ 30 mg/mmol ( female male ) .. 8 . The subject capable give write informed consent , include compliance requirement restriction list consent form . 9 . A female subject eligible participate : Nonchildbearing potential Childbearing potential agrees use acceptable form contraception . 10 . Male subject must agree use one contraception method list 11 . ALT &lt; 2xULN ; alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 12 . Single Average QTc , QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . 1 . Current evidence , history within last 7 day , influenzalike illness define fever ( &gt; 38°C ) two follow symptom : cough , sore throat , runny nose , sneeze , limb / joint pain , headache , vomit / diarrhoea absence know cause , influenza . 2 . Use antiinflammatory drug include corticosteroid , chronic maintenance therapy NSAIDs , antiTumor Necrosis Factor ( antiTNF ) antiInterleukin1 ( antiIL1 ) within 60 day prior dose . 3 . Current evidence ongoing acute infection , history repeat , chronic opportunistic infection ( e.g . recurrent folliculitis , cutaneous infection repeat pneumonia ) history serious bacterial infection within 6 month randomisation . 4 . History malignancy significant cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal condition . 5 . History chronic granulomatous infection , Mycobacterium tuberculosis previous Mycobacterium infection . 6 . Creatinine clearance less 60ml/min 7 . Screens positive Hepatitis B surface antigen , Hepatitis C antibody Human Immunodeficiency Virus ( HIV ) 8 . History severe allergic reaction , anaphylaxis immunodeficiency . 9 . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . 10 . A positive prestudy drug/alcohol screen . 11 . History regular alcohol consumption within 6 month study 12 . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . 13 . Exposure four new chemical entity within 12 month prior first dose day . 14 . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication . 15 . History sensitivity study medication , component thereof 16 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . 17 . Pregnant female determine positive serum urine hCG test screening . 18 . Lactating female . 19 . Unwillingness inability follow procedure outline protocol . 20 . Subject mentally legally incapacitate . 21 . Subject receive live attenuate vaccine ( ) within 30 day randomisation require vaccination live attenuate vaccine prior end study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>Obese</keyword>
	<keyword>T2DM</keyword>
	<keyword>IL-18</keyword>
	<keyword>Monoclonal antibody ( mAb )</keyword>
</DOC>